---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010489"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:17:39.456482+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata reports Q2 2023 cash $8.4M; FDA agrees Phase 3 design for DMT310 acne

## Summary
- Cash $8.4M at June 30, 2023 vs $6.2M at Dec 31, 2022; net $5.7M from two 2023 financings.
- FDA agreed Phase 3 program acceptable for NDA; co-primary endpoints acceptable.
- Phase 3 STAR-1 study for DMT310 acne expected to start enrollment in 2H 2023.
- R&D expenses $0.8M Q2 2023 vs $1.6M Q2 2022; G&A $0.9M vs $1.1M.
- Cash resources expected to fund operations into Q2 2024.

## SEC filing metadata
- accession: 0001654954-23-010489
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/0001654954-23-010489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010489
- JSON: https://secwatch.observer/filing/0001654954-23-010489.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010489.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.4 million in cash and cash equivalents.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $8.4 million in cash and cash equivalents
  - Result: reported results
  source text: to pursue partnership discussions for its DMT410 program for the topical delivery of botulinum toxin. Second Quarter 2023 Financial Results As of June 30, 2023, Dermata had $8.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equivalents resulted from $5.7 million net proceeds from the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/0001654954-23-010489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.